MedPath

Teva Pharmaceuticals Launches Generic Octreotide Acetate for Injectable Suspension

  • Teva Pharmaceuticals has launched the first generic version of Sandostatin LAR Depot in the U.S., offering a new treatment option.
  • The generic octreotide acetate is indicated for treating acromegaly and severe diarrhea associated with carcinoid syndrome.
  • Sandostatin LAR Depot, the branded version, recorded annual sales of $826 million as of July 2024, indicating a substantial market.
  • This launch provides a more accessible alternative for patients requiring this important medication, according to Teva.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, has announced the launch of its generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This marks the availability of the first and only generic equivalent to this important medication.
The newly launched octreotide acetate is indicated for the treatment of acromegaly, a hormonal disorder that develops when the pituitary gland produces too much growth hormone, and for managing severe diarrhea associated with carcinoid syndrome, a condition caused by tumors that secrete certain chemicals into the bloodstream.
"With today's launch of octreotide acetate for injectable suspension, Teva is providing patients a new option for this important treatment," said Ernie Richardsen, SVP U.S. Commercial Generics.
The introduction of a generic alternative to Sandostatin LAR Depot is significant, considering the branded drug's substantial market presence. Sandostatin LAR Depot recorded annual sales of $826 million as of July 2024. The availability of a generic version is expected to provide a more cost-effective option for patients requiring this treatment, potentially increasing access to this essential medication. The drug is administered via injection.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Accepts Crinetics' Paltusotine NDA for Acromegaly Treatment

The FDA has accepted Crinetics Pharmaceuticals' NDA for paltusotine for acromegaly, setting a target action date of September 25, 2025.

Aurobindo Pharma's Eugia Pharma Receives USFDA Approval for Generic Pazopanib Tablets

Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, has secured USFDA approval to manufacture and market Pazopanib Tablets (200 mg) in the US.

FDA Approves New Treatments for Severe Pain, UTIs, RSV, Hemophilia B, and Autoimmune Diseases

The FDA has approved oxycodone hydrochloride (Roxybond) for managing severe pain when alternative treatments are inadequate, addressing a critical need for effective pain relief.

FDA Approves New Intravenous Formulation of Ustekinumab Biosimilar SELARSDI™

The FDA has approved a new intravenous formulation of SELARSDI™ (ustekinumab-aekn), a biosimilar to STELARA® (ustekinumab), expanding its potential use.

FDA Approves Alvotech and Teva's SELARSDI (ustekinumab-aekn) for Crohn's Disease and Ulcerative Colitis

The FDA has approved a new intravenous infusion presentation of SELARSDI, expanding its label to include Crohn’s disease and ulcerative colitis.

Ariceum Therapeutics Presents Promising Data on 225Ac-Satoreotide at EANM 2024

Ariceum Therapeutics showcased significant findings on 225Ac-Satoreotide, a novel radiopharmaceutical, at the European Association of Nuclear Medicine 2024 conference. The drug demonstrated superior anti-tumour efficacy and pharmacokinetic profile compared to DOTA-TATE, marking a potential breakthrough in treating SSTR2-positive cancers.

FDA Approves New IV Infusion Presentation of Selarsdi (ustekinumab-aekn) Biosimilar

The FDA has approved a new intravenous infusion formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential use.

Cadrenal Therapeutics' Tecarfarin Advances to Phase 3 for Thrombosis Prevention

Cadrenal Therapeutics is advancing tecarfarin, a novel oral anticoagulant, into a Phase 3 trial for preventing blood clots in patients with left ventricular assist devices (LVADs).

KalVista Seeks Global Approval for Oral HAE Treatment Sebetralstat

KalVista Pharmaceuticals has submitted Marketing Authorization Applications (MAAs) for sebetralstat in the UK, Switzerland, Australia, and Singapore.

Acadia To Seek First-Ever FDA Approval in Rett Syndrome

Acadia Pharmaceuticals' shares increased following positive late-stage data from a Phase III study of trofinetide for Rett syndrome, indicating the drug's potential effectiveness and safety. The company plans to submit a New Drug Application by mid-2022.

Reference News

[1]
Teva Pharma Launches Octreotide Acetate For Injectable Suspension - Quick Facts
markets.businessinsider.com · Oct 1, 2024

Teva Pharmaceuticals launches the first generic version of Sandostatin LAR Depot in the U.S., indicated for treating acr...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy